KBIO News Alert Kalobios Pharmaceuticals Inc (KBIO) 1.66 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Kalobios Pharmaceuticals Inc (KBIO) 1.66 $KBIO

Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.66 (-0.05), GILD: 100.46 (-2.70), GERN: 3.04 (+0.06), ONTX: 3.94 (-0.12), CTIC: 2.21 (-0.01), BMY: 57.69 (-0.86), STML: 15.28 (-0.21), NVS: 91.65 (+0.01), MEIP: 3.95 (-0.12), CELGZ: 3.29 (-0.18), XLRN: 37.63 (-0.37)

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 102.76 (-1.20), KBIO: 1.66 (-0.05), PFE: 30.67 (-0.19), ADMP: 5.38 (+0.26), GSK: 41.92 (+0.62), NVS: 91.65 (+0.01), FPRX: 21.92 (+0.07)

KaloBios names Robert A. Baffi to board
M2 - Mon Dec 01, 7:32AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) revealed on Monday the addition of Dr. Robert A. Baffi, Ph.D. to its board of directors.
BMRN: 86.06 (-1.17), KBIO: 1.66 (-0.05)

KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
PR Newswire - Mon Dec 01, 7:05AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Robert A. Baffi, Ph.D. to the KaloBios Board of Directors. Dr. Baffi is Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).
BMRN: 86.06 (-1.17), KBIO: 1.66 (-0.05)

Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 91.05 (-1.12), KBIO: 1.66 (-0.05), AKRX: 37.55 (-2.17), MYL: 53.56 (-0.96)

KaloBios Announces Upcoming Scientific and Investor Conference Participation
PR Newswire - Tue Nov 11, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the Stifel 2014 Healthcare Conference in November, and that data on the company's KB004 program in hematologic malignancies will be presented in a poster session at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in early December.
KBIO: 1.66 (-0.05)

KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 91.05 (-1.12), IPXL: 29.09 (-1.55), KBIO: 1.66 (-0.05), MYL: 53.56 (-0.96)

KaloBios Pharmaceuticals beats by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:38PM CST

KBIO: 1.66 (-0.05)

KaloBios Reports Third Quarter Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the third quarter of 2014.
KBIO: 1.66 (-0.05)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.67 (-0.19), INCY: 71.62 (-0.52), ONTX: 3.94 (-0.12), BMY: 57.69 (-0.86), GSK: 41.92 (+0.62), STML: 15.28 (-0.21), SNTA: 2.66 (+0.02), KBIO: 1.66 (-0.05), BPTH: 2.58 (+0.14), CELGZ: 3.29 (-0.18), NVS: 91.65 (+0.01)

NeoStem Announces Additions to Management
GlobeNewswire - Wed Nov 05, 6:46AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel cell based therapeutics, announced today the addition of three experienced leaders in the biotech industry to its management team. Harry Lam, Ph.D., Ann M. Daus, Ph.D., and Anna Crivici, Ph.D. bring a breadth of experience in leading high performing teams to meet operational goals.
KBIO: 1.66 (-0.05), NBS: 3.23 (+0.01)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 7.08 (-0.31), NEO: 4.13 (+0.04), AU: 7.52 (+0.04), FNHC: 24.46 (unch), AMS: 2.37 (-0.10), NYMX: 0.41 (+0.01), AMDA: 0.64 (-0.02), CVD: 102.05 (+0.43), GBIM: 6.85 (unch), RCAP: 10.90 (+0.44), KBIO: 1.66 (-0.05), COOL: 0.59 (-0.04), SAPE: 24.79 (-0.04), XTLB: 2.51 (+0.01), GERN: 3.04 (+0.06), ANIP: 55.08 (+1.32), BBLU: 1.10 (+0.23), NXTD: 2.34 (-0.05), AP: 17.49 (-0.13), ALQA: 3.94 (-0.04)

Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:25AM CDT
Cerulean Pharma (CERU) was a big mover last session, with shares surging nearly 31% on the day.
MNK: 91.05 (-1.12), KBIO: 1.66 (-0.05), AKRX: 37.55 (-2.17), CERU: 6.15 (-0.09)

Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
PR Newswire - Thu Aug 14, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels. The expression and function of EphA3 in the tumor microenvironment but not in adult normal tissues together with the favorable safety profile as observed thus far in a Phase 1-2 clinical study, where infusion reactions have been the most common adverse event, supports the development of KB004 (KaloBios' Humaneered® anti-EphA3 monoclonal antibody [mAb]) as a potential treatment for both hematologic and solid tumors.
KBIO: 1.66 (-0.05)

KaloBios (KBIO) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 9:04AM CDT
KaloBios (KBIO) Enters Oversold Territory
KBIO: 1.66 (-0.05)

Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:46AM CDT
Relypsa (RLYP) was a big mover last session, with shares rising over 13% on the day.
MNK: 91.05 (-1.12), KBIO: 1.66 (-0.05), AKRX: 37.55 (-2.17), RLYP: 31.59 (-1.40)

KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on its current clinical programs and announced financial results for the second quarter of 2014.
KBIO: 1.66 (-0.05)

KaloBios Provides Update on KB001-A Partnership and Clinical Status
PR Newswire - Mon Jul 28, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.
KBIO: 1.66 (-0.05)

Cutera, Inc. (CUTR) in Focus: Stock Adds 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:11AM CDT
Cutera, Inc. (CUTR) was a big mover last session, as the company saw its shares rise over 7% on the day.
KBIO: 1.66 (-0.05), AKRX: 37.55 (-2.17), AERI: 28.04 (-1.08), CUTR: 9.74 (+0.02)

5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Jun 26, 12:56PM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
HEAR: 3.48 (-0.11), NWBO: 4.94 (-0.02), KBIO: 1.66 (-0.05), SFUN: 6.84 (-0.66), ONTX: 3.94 (-0.12), PRAN: 1.84 (-0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 110

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 93

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 167

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 118

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 165

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 205

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 87

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Avaline's Organic Wines Shine in New Holiday Campaign

Updated Category News Views 250

Avaline Unveils Its Charming Holiday Campaign The organic wine brand Avaline is excited to kick off its holiday campaign, which beautifully captures the spirit of the season. By blending nostalgia with festive cheer, Avaline invites everyone to relish the little moments that make the holidays special. The campaign draws inspiration from beloved holiday films, reminding us...

Continue Reading
Exploring In-Game Advertising: Key Insights for Brands

Updated Category News Views 206

Unlocking the Potential of In-Game Advertising Recent research conducted by Cint sheds light on the rising value of in-game advertising (IGA) for brands and the necessity for measurement standards within this dynamic marketing field. Video games have increasingly become a vital platform for advertisers, offering rich engagement opportunities. Consumers are showing...

Continue Reading
Mawson Infrastructure Reports Significant Operational Growth

Updated Category News Views 66

Update on Mawson Infrastructure Group's Operations Mawson Infrastructure Group Inc. recently released a significant operational update that highlights impressive growth in its digital colocation sector. The figures show a remarkable 166% increase in digital colocation revenue compared to a year ago, specifically in August 2023, and a solid 25% growth from the previous...

Continue Reading
Cybersecurity Landscape Evolves: New Threats and Insights

Updated Category News Views 292

An Overview of Current Cybersecurity Threats The digital landscape is becoming increasingly complex, and organizations are challenged with new and emerging cybersecurity threats. Red Canary's recent report dives deep into these threats, highlighting alarming trends that security teams must address now. The Rise of Identity Attacks As technology continues to advance, so do...

Continue Reading
US Family Health Plan Brighton Marine Celebrates Recognition with Awards

Updated Category News Views 188

US Family Health Plan Brighton Marine Honored with Excellence Awards Recent accolades reflect the dedication and quality of care provided by US Family Health Plan Brighton Marine. This esteemed organization has been awarded three Human Experience Pinnacle of Excellence Awards, recognizing it as one of the top health plans across the nation. Such recognition highlights the...

Continue Reading